sodium phenylbutyrate and taurursodiol
for oral suspension Initial U.S. Approval: 2022
RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.
Facts about taurusodiol and sodium phenylbutyrate
Approval Date: 2014
Proprietary Name: RELYVRIO (sodium phenylbutyrate and taurursodiol)
Active Ingredient(s): sodium phenylbutyrate and taurursodiol
FDA-approved use: amyotrophic lateral sclerosis (ALS)
Dosage Form: For oral suspension: 3 g sodium phenylbutyrate and 1 g taurursodiol in singledose packets
Medicine Approved By: US FDA
Manufacturer Amylyx Pharmaceuticals, Inc
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “taurusodiol and sodium phenylbutyrate” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For taurusodiol and sodium phenylbutyrate
Approved accessible "taurusodiol and sodium phenylbutyrate"
Relyvrio (taurusodiol and sodium phenylbutyrate) powder for oral solution to treat amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.
Sodium phenylbutyrate/ursodoxicoltaurine is indicated for the treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate/ursodoxicoltaurine, also known as sodium phenylbutyrate/taurursodiol and sold under the brand name Albrioza among others, is a fixed-dose combination medication used for the treatment of amyotrophic lateral sclerosis (ALS). It contains sodium phenylbutyrate and ursodoxicoltaurine (taurursodiol) The combination was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022
How To access taurusodiol and sodium phenylbutyrate?
RELYVRIO (sodium phenylbutyrate and taurursodiol) for oral suspension Initial U.S. Approval: 2022
To access taurusodiol and sodium phenylbutyrate sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa